Their findings were confirmed in MS patients using the same method, with increased levels of both pro-IL-16 and bioactive IL-16 observed in the CNS lesions of patients compared to controls, with the levels peaked in acute and diminished in subacute lesions [12,25]. This evidence concerns the gene IL16 and myeloid sarcoma.